Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | TTR | P02766 | 1/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 7/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | XBP1 | P17861 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | LPL | P06858 | 1/20 | 0.34 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29955406 | 1.00 | ENPP2 (0.44) | ENPP2RECQLNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL22928848 | 0.79 | IDO1 (0.40) | ENPP2SMN1; SMN2HPGDTP53IDO1 | |
| SCHEMBL29653364 | 0.77 | ENPP2 (0.45) | ENPP2RECQLS1PR1HSD17B10LPL | |
| SCHEMBL3791071 | 0.77 | ENPP2 (0.45) | ENPP2RECQLTTRHSD17B10MAPT | |
| SCHEMBL24456142 | 0.77 | ENPP2 (0.45) | ENPP2RECQLS1PR1HSD17B10LPL | |
| SCHEMBL7962703 | 0.75 | CYP4F2 (0.47) | ENPP2HSD17B10SLC6A2SLC6A4LPL | |
| SCHEMBL29954459 | 0.75 | CYP4F2 (0.47) | ENPP2HSD17B10SLC6A2SLC6A4LPL | |
| SCHEMBL3786642 | 0.75 | ENPP2 (0.44) | ENPP2RAB9AHPGDHSD17B10SLC6A2 | |
| SCHEMBL92905 | 0.75 | IDO1 (0.58) | RECQLSMN1; SMN2S1PR1HSD17B10IDO1 | |
| SCHEMBL623389 | 0.74 | SMN1; SMN2 (0.65) | SMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115477741-B | Degradable polymer and preparation method and application thereof | 浙江中医药大学 | 2023-08-18 | — | — | CN | claimed |
| CN-115477741-A | Degradable polymer and preparation method and application thereof | 浙江中医药大学 | 2022-12-16 | — | — | CN | claimed |
| US-12492182-B2 | Hydroxytriazine compounds and pharmaceutical use thereof | JAPAN TOBACCO INC. (JP) | 2025-12-09 | — | — | US | disclosed |
| US-12398111-B2 | Triazine compounds and pharmaceutical use thereof | JAPAN TOBACCO INC. (JP) | 2025-08-26 | — | — | US | disclosed |
| US-20250206724-A1 | SUBSTITUTED 3-AMINO INDAZOLE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2025-06-26 | — | — | US | disclosed |
| US-20240076278-A1 | HYDROXYTRIAZINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2024-03-07 | — | — | US | disclosed |
| US-20240059703-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE | AMGEN INC. | 2024-02-22 | — | — | US | disclosed |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| WO-2023186773-A1 | SUBSTITUTED 3-AMINO INDAZOLE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2023-10-05 | — | — | WO | disclosed |
| CN-115477741-B | Degradable polymer and preparation method and application thereof | 浙江中医药大学 | 2023-08-18 | — | — | CN | disclosed |
| US-20230086702-A1 | SUBSTITUTED 2-AMINO-PYRAZOLYL-[1,2,4]TRIAZOLO[1,5A]PYRIDINE DERIVATIVES AND USE THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2023-03-23 | — | — | US | disclosed |
| US-8487102-B2 | Pyrrazolopyridine compounds as dual NK1/NK3 receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-20130158002-A1 | POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 | MERCK SHARP & DOHME LLC | 2013-06-20 | — | — | US | disclosed |
| US-20130158002-A1 | POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 | MERCK SHARP & DOHME LLC | 2013-06-20 | — | — | US | disclosed |
| EP-2560974-A1 | PYRRAZOLOPYRIDINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2013-02-27 | — | — | EP | disclosed |
| WO-2012168162-A1 | BENZOCYCLOHEPTENE ACETIC ACIDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-12-13 | — | — | WO | disclosed |
| US-20120309796-A1 | BENZOCYCLOHEPTENE ACETIC ACIDS | FIROOZNIA FARIBORZ (US) | 2012-12-06 | — | — | US | disclosed |
| WO-2011131571-A1 | PYRRAZOLOPYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-10-27 | — | — | WO | disclosed |
| US-20110257402-A1 | PYRRAZOLOPYRIDINE COMPOUNDS AS DUAL NK1/NK3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-10-20 | — | — | US | disclosed |
| WO-2011109277-A1 | POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 | MERCK SHARP & DOHME CORP. (US) | 2011-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158002-A1 | POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 | GRM2, GRM1, GRM3 | ENPP2 609/4885RECQL 3830/4885NPC1 2611/4885 |
| US-20250206724-A1 | SUBSTITUTED 3-AMINO INDAZOLE DERIVATIVES AS KINASE INHIBITORS | CDK1, CDK11A, CDK3 | ENPP2 1794/4885RECQL 1594/4885NPC1 2887/4885 |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | CGAS, GLS2, GLS | ENPP2 517/4885RECQL 13/4885NPC1 667/4885 |
| US-20110257402-A1 | PYRRAZOLOPYRIDINE COMPOUNDS AS DUAL NK1/NK3 RECEPTOR ANTAGONISTS | TACR2, GRIN3A, TACR1 | ENPP2 1982/4885RECQL 4786/4885NPC1 990/4885 |
| US-20240076278-A1 | HYDROXYTRIAZINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | PTGS1, PTGIS, PTGES | ENPP2 637/4885RECQL 1243/4885NPC1 1470/4885 |
| US-12492182-B2 | Hydroxytriazine compounds and pharmaceutical use thereof | PTGS1, PTGIS, PTGES | ENPP2 637/4885RECQL 1243/4885NPC1 1470/4885 |
| US-20240059703-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE | KRAS, HRAS, APC | ENPP2 3352/4885RECQL 163/4885NPC1 2511/4885 |
| US-20120309796-A1 | BENZOCYCLOHEPTENE ACETIC ACIDS | ACAT2, ACAT1, CYP27A1 | ENPP2 557/4885RECQL 3757/4885NPC1 1167/4885 |
| US-12398111-B2 | Triazine compounds and pharmaceutical use thereof | PTGIS, PTGS1, PTGES | ENPP2 316/4885RECQL 1553/4885NPC1 998/4885 |
| US-20230086702-A1 | SUBSTITUTED 2-AMINO-PYRAZOLYL-[1,2,4]TRIAZOLO[1,5A]PYRIDINE DERIVATIVES AND USE THEREOF | SNCA, PSEN2, PRNP | ENPP2 2265/4885RECQL 542/4885NPC1 401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.